http://rdf.ncbi.nlm.nih.gov/pubchem/reference/36378150

Outgoing Links

Predicate Object
contentType Journal Article
issn 0344-0338
pageRange 155008-
publicationName Pathology - Research and Practice
startingPage 155008
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_ec6a02b8e992899dadae9c472676f56c
bibliographicCitation Mollica V, Tassinari E, Santoni M, Marchese PV, Giunchi F, Maloberti T, Tateo V, Ricci C, Rosellini M, Marchetti A, Fiorentino M, Biase DD, Massari F. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab. Pathology - Research and Practice. 2024 Jan;253():155008. doi: 10.1016/j.prp.2023.155008.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1bec5a01c3e42bdda90d7ce1c248599c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d13cd0996546427244204aec3dd0b949
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3ba3a433be1bac56e654bf45bbb551cb
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b643967958f71dd6a0768d25345a476c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8ae35a38fcfbc4d9ef6e751d03204e7a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_610e88b28bff7c793c2844d184b2a639
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7ed037512611fc886f8643895c63bd6b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0eb6dca6518538c655afe625900fbe3d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3936d9a80946e6efd0fa87139f075c5e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d2035d76a7672a5008b5bfd65f2b1630
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7d0a59d26d742e096e18915463133038
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bf18e09ab864d817c74e413e6f5efe47
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-5169-3631
date 202401
identifier https://pubmed.ncbi.nlm.nih.gov/38103361
https://doi.org/10.1016/j.prp.2023.155008
isPartOf https://portal.issn.org/resource/ISSN/0344-0338
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/6536
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
discusses http://id.nlm.nih.gov/mesh/M0017026
http://id.nlm.nih.gov/mesh/M0273402
http://id.nlm.nih.gov/mesh/M0586473
http://id.nlm.nih.gov/mesh/M0028508
http://id.nlm.nih.gov/mesh/M0556300
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D001749Q000235
http://id.nlm.nih.gov/mesh/D061067
http://id.nlm.nih.gov/mesh/D002295Q000188
http://id.nlm.nih.gov/mesh/D002295Q000235
http://id.nlm.nih.gov/mesh/D019098Q000235
http://id.nlm.nih.gov/mesh/D001749Q000188
http://id.nlm.nih.gov/mesh/D001749Q000473
hasSubjectTerm http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D012189
http://id.nlm.nih.gov/mesh/D010984Q000627
http://id.nlm.nih.gov/mesh/D009154Q000235

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID7015

Total number of triples: 46.